The metabolic profile of mitoxantrone and its relation with mitoxantrone-induced cardiotoxicity

Archives of Toxicology

Volumn 87, Issue 10, 2013, Pages 1809-1820

  Rossato, Luciana Grazziotin ^a   Costa, Vera Marisa ^a   De Pinho, Paula Guedes ^a   Arbo, Marcelo Dutra ^a   De Freitas, Victor ^a   Vilain, Laure ^a   De Lourdes Bastos, Maria ^a   Palmeira, Carlos ^b   Remião, Fernando ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Bioactivation; Cardiotoxicity; LC MS; Metabolism; Mitoxantrone; S9 fraction

Indexed keywords

8,11 DIHYDROXY 4 (2 HYDROXYETHYL) 6 [[2 [(2 HYDROXYETHYL)AMINO]ETHYL]AMINO] 1,2,3,4,7,12 HEXAHYDRONAPHTO[2,3]QUINOXALINE 7 12 DIONE; ACETOXY ESTER DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 2E1; DRUG METABOLITE; ESTER DERIVATIVE; GLUTATHIONE; MITOXANTRONE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONJUGATE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; HEART; INCUBATION TIME; LIQUID CHROMATOGRAPHY; LIVER; MALE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HEART; HEART DISEASES; LIVER; MALE; MITOXANTRONE; RATS; RATS, WISTAR; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84884221582     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-013-1040-6     Document Type: Article

References (36)

1. An G, Morris ME (2010) HPLC analysis of mitoxantrone in mouse plasma and tissues: application in a pharmacokinetic study. J Pharm Biomed Anal 51(3):750-753
2. Avasarala JR et al (2003) Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 9:59-62
3. Basra J et al (1985) Evidence for human liver mediated-free radical formation by doxorubicin and mitozantrone. Anticancer Drug Des 1:45-52
4. Batra VK et al (1986) Pharmacokinetics of mitoxantrone in man and laboratory animals. Drug Metab Rev 17:311-329
5. Blanz J et al (1991) Evidence for oxidative activation of mitoxantrone in human, pig, and rat. Drug Metab Dispos 19(5):871-880
6. Brandon EF et al (2003) An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 189(3):233-246
7. Brück TB, Brück DW (2011) Oxidative metabolism of the anti-cancer agent mitoxantrone by horseradish, lacto-and lignin peroxidase. Biochimie 93(2):217-226
8. Butler J, Hoey BM (1987) Are reduced quinones necessarily involved in the antitumour activity of quinone drugs? Br J Cancer 8:53-59
9. Canal P et al (1993) Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. Cancer Res 53(20):4850-4854
10. Duthie SJ, Grant MH (1989) The role of reductive and oxidative metabolism in the toxicity of mitoxantrone, adriamycin and menadione in human liver derived Hep G2 hepatoma cells. Br J Cancer 60(4):566-571
11. Ehninger G et al (1990) Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet 18(5):365-380
12. Feofanov A et al (1997) Quantitative confocal spectral imaging analysis of mitoxantrone within living K562 cells: intracellular accumulation and distribution of monomers, aggregates, naphtoquinoxaline metabolite, and drug-target complexes. Biophys J 73(6):3328-3336
13. Fisher GR, Patterson LH (1992) Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin. Cancer Chemother Pharmacol 30(6):451-458
14. Fisher G, Patterson LH, Gutierrez PL (1993) A comparison of free radical formation by quinone anti-tumour agents in MCF-7 cells and the role of NAD(P)H (quinone-acceptor) oxidoreductase (DT-diaphorase). Chem Biol Interact 88:137-153
15. Hsin L-W et al (2008) Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates. Bioorg Med Chem 16(2):1006-1014
16. Jia L, Liu X (2007) The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr Drug Metab 8(8):822-829
17. Khan SN et al (2010) Effect of mitoxantrone on proliferation dynamics and cell cycle progression. Biosci Rep 30(6):375-381
18. Kostrzewa-Nowak D et al (2007) Bioreductive activation of mitoxantrone by NADPH cytochrome P-450 reductase. Implications for increasing its ability to inhibit the growth of sensitive and multidrug resistant leukaemia HL60 cells. Cancer Lett 245(1-2):252-262
19. Li SJ, Rodgers EH, Grant MH (1995) The activity of xenobiotic enzymes and the cytotoxicity of mitoxantrone in MCF 7 human breast cancer cells treated with inducing agents. Chem Biol Interact 97(2):101-118
20. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent, J Biol Chem (193):265-272
21. Mewes K et al (1993) Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates. Cancer Res 53(21):5135-5142
22. Neuhaus O, Kieseier BC, Hartung H-P (2006) Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol Ther 109(1-2):198-209
23. Novak RF, Kharasch ED (1985) Mitoxantrone: propensity for free radical formation and lipid peroxidation-implications for cardiotoxicity. Invest New Drugs 3(2):95-99
24. Panousis C, Kettle AJ, Phillips DR (1997) Neutrophil-mediated activation of mitoxantrone to metabolites which form adducts with DNA. Cancer Lett 113(1-2):173-178
25. Parkinson A, Ogilvie B (2008) Biotransformation of xenobiotics. In: Klaassen C (ed) Casarett & Doull's toxicology: the basic science of poisons. McGraw-Hill, New York, p 1331
26. Pontes H et al (2010) Metabolic interactions between ethanol and MDMA in primary cultured rat hepatocytes. Toxicology 270(2-3):150-157
27. Richard B et al (1991) Interspecies variability in mitoxantrone metabolism using primary cultures of hepatocytes isolated from rat, rabbit and humans. Biochem Pharmacol 41(2):255-262
28. Rossato LG et al (2011) Structural isomerization of synephrine influences its uptake and ensuing glutathione depletion in rat-isolated cardiomyocytes. Arch Toxicol 85(8):929-939
29. Sardão V et al (2009a) Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts. Cancer Chemother Pharmacol 64(4):811-827
30. Sardão V et al (2009b) Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets. Cell Biol Toxicol 25(3):227-243
31. Seiter K (2005) Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf 4(2):219-234
32. Shipp NG et al (1993) Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells. Cancer Res 53(3):550-556
33. Silva R et al (2011) In vitro study of P-glycoprotein induction as an antidotal pathway to prevent cytotoxicity in Caco-2 cells. Arch Toxicol 85(4):315-326
34. Wolf CR, Macpherson JS, Smyth JF (1986) Evidence for the metabolism of mitozantrone by microsomal glutathione transferases and 3-methylcholanthrene- inducible glucuronosyl transferases. Biochem Pharmacol 35(9):1577-1581
35. Yoshihara S et al (2001) Metabolic activation of bisphenol A by rat liver S9 fraction. Toxicol Sci 62(2):221-227
36. Zordoky BNM, El-Kadi AOS (2007) H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. J Pharmacol Toxicol Methods 56(3):317-322